1. Technology Overview
Results obtained from microarray analysis and validated by semi-quantitative RT-PCR and real-time RT-PCR in human hepatoma cells line, HepG2, revealed that the crude extract from Tamarindus indica (T. indica) fruit pulp up-regulated genes related to antioxidant activity including CYP3A1, GSTA1, GSTA2, GSTO2 and SULTIA2. The extracts were also able to up-regulate the transcription of apoA4 and apoA5 genes while down regulate that of MTTP. ApoA-V is thought to reduce TG levels by activating lipoprotein lipase (LPL), the enzyme that is responsible for catabolizing TG-rich lipoproteins, chylomicrons and VLDL hence improving the clearance of these lipoproteins from the blood. ApoA-IV, on the other hand, had been shown to be a potent endogenous antioxidant that inhibits lipid oxidation. MTTP is required for the assembly and secretion of TG-rich lipoproteins from both enterocytes and hepatocytes. MTTP inhibitor has the potential to lower plasma lipid mainly plasma TG. The inhibition of MTTP gene expression especially in the intestine may subsequently lead to the reduction in the levels of blood cholesterol. In addition, the transcription of the pituitary tumour-transforming gene (PTTGI) was down-regulated. An increase in the levels of PTTGI is seen in stage III of various cancers including thyroid, pituitary, lung, colon, oesophagus, ovary and breast cancers. The crude extract of the fruits of T. indica has potential application for the treatment of cancer through the inhibition of the transcription of PTTGI gene.
- UMCIC File Number: 628/192
- Patent: MY-158583-A
- Patent status: Granted
- Malaysia patent: Tamarindus Indica:Therapeutic Properties Of Crude Extract Of The Fruits
- This technology is currently available for licensing and commercialisation.